Posted by Michael Wonder on 09 May 2021
‘In their own bubble’: How a cancer center promoted an exclusive experimental drug to attract patients
6 May 2021 - A new medication for children with a rare and life-threatening cancer called neuroblastoma had a curious path to approval last November: with one exception, all U.S. patients in the clinical trials were treated at Memorial Sloan Kettering Cancer Center.
For almost a decade, naxitamab — now one of the most expensive drugs on the market, at $733,248 for a six month regimen — was available in the U.S. only at the prestigious New York cancer hospital.
